The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma

BMC Cancer

Research

Wenxian Wang¹  Jinfei Si²  Xiaodong Gu²  Yue Hao²  Jing Xiang²  Jingwen Wei³  Yan Sun³  Yelan Guan³ 

[1] Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer hospital), 310022, Hangzhou, Zhejiang, China;Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022, Hangzhou, Zhejiang, China;Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer hospital), 310022, Hangzhou, Zhejiang, China;Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022, Hangzhou, Zhejiang, China;The Second Clinical Medical College of Zhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China;Wenzhou Medical University, 325035, Wenzhou, Zhejiang, China;Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer hospital), 310022, Hangzhou, Zhejiang, China;Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022, Hangzhou, Zhejiang, China;

关键词: Thymic carcinoma;    Apatinib;    Anlotinib;    Anti-angiogenic drugs;    Efficacy;   

DOI  :  10.1186/s12885-022-10448-z

 received in 2022-09-04, accepted in 2022-12-14,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundAntiangiogenic drugs have shown initial efficacy in the treatment of advanced thymic carcinomas (TCs); however, data are limited. In this study, we provide real-world data relating to the efficacy of antiangiogenic drugs for the treatment of patients with TCs.MethodsWe retrospectively collected data on clinical progress after first-line chemotherapy in TCs patients who were treated with small molecule antiangiogenic drugs at our institution between January 2010 and December 2021. Tumor response was evaluated according to version 1.1 of the Response Evaluation Criteria in Solid Tumors. Progression free survival and overall survival were calculated using the Kaplan-Meier method.ResultsOf the 17 patients enrolled, 13 (76.5%) received apatinib and four (23.5%) anlotinib monotherapy with an objective response rate of 23.5%. Eleven (64.7%) patients had stable disease. The median follow-up period was 46.0 months (95% confidence interval [CI], 33.0–59.0 months). The median progression survival and overall survival were 7.9 months (95% CI, 6.5–9.3) and 47.0 months (95% CI, 35.4–58.6), respectively. In the 13 patients receiving apatinib, the median PFS was 7.0 months (95% CI, 5.0–9.0), compared with 8.0 months (95% CI, 2.7–13.3 months) for patients in the anlotinib group (P = 0.945). The most common grade 3 adverse events (AEs) were hypertension (n = 3, 23.1%), followed by proteinuria and hand-foot syndrome (HFS, n = 2, 15.4%). There were no grade 4 AEs although eight patients (47.1%) required mid-course discontinuation.ConclusionFor refractory TCs, small molecule antiangiogenic drugs are efficacious as second- or post-line treatments. The toxicity of antiangiogenic therapy is manageable.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq525.gif

41116_2022_35_Article_IEq522.gif

41116_2022_35_Article_IEq520.gif